<DOC>
	<DOCNO>NCT02291380</DOCNO>
	<brief_summary>A study , multi-center , randomize , double-blind , placebo parallel-controlled method , carry evaluate safety efficacy Botulinum Toxin Type A injection ( HengLi® ) prophylactic treatment chronic migraine adult . In core phase , two treatment HengLi® placebo administrate ( randomize ratio 2:1 , target number 288 subject ) . In extension phase , three treatment HengLi® still administrate 288 subject recruit ever .</brief_summary>
	<brief_title>A Study Evaluate Botulinum Toxin Type A Injection（HengLi®）for Prophylactic Treatment Chronic Migraine</brief_title>
	<detailed_description>Subjects core phase randomize two group : Botulinum Toxin Type A ( HengLi® ) ( 155U 195U ) placebo . Study include 28-day baseline screening period , 24-week core phase 2 administration , 32-week extension phase 3 administration .Subjects enrol get e-headache-diary record headache symptom acute headache medication . HengLi® administer 31 fixed-site , fixed-dose ( 5U ) , i.m . injection across 7 specific head/neck muscle area every 12 week ( week 0 , 12 , 24 , 36 , 48 ) . At investigator 's discretion , 40 U additional HengLi® could administer among 3 muscle group ( occipitalis , temporalis , trapezius ) use protocol-defined paradigm . Hence maximum dose per treatment cycle 195 U 39 site . Efficacy Outcome Measures evaluate headache diary , HIT-6 score MIDAS score . The primary Outcome Measure : Change baseline average number day headache per month ( The last 4 week core phase 4 week baseline period compare number headache day per month average . )</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Age≥18 ≤65 , male female ; Subjects voluntarily sign informed consent . Patients comply ICHD3 ( β ) diagnostic criterion chronic migraine . Females pregnant , nursing , plan pregnancy study period , female childbearing potential , use reliable mean contraception ; Known allergy sensitivity study medication component ; Subjects accept prophylactic treatment migraine ( e.g . propranolol , metoprolol , bisoprolol , flunarizine , valproate , topiramate , gabapentin , naproxen , aspirin , amitriptyline , candesartan , lisinopril , etc . ) within 4 week screen ; Subjects cardiac functional insufficiency ; Subjects renal insufficiency ( serum creatinine &gt; 1.5 time ULN ) ; Subjects hepatic disease ( ALT AST &gt; twice ULN ) ; Subjects systemic myoneural junction disease ( e.g . myasthenia , EatonLambert syndrome , amyotrophic lateral sclerosis , etc . ) ; Subjects history facial palsy ; Infection dermatological condition injection site ; Patients type migraine comply diagnostic criterion chronic migraine ; Subjects ever take type botulinum toxin therapy past 6 month ; Subjects use aminoglycoside antibiotic recent week need use aminoglycoside antibiotic conduct clinical study ; Subjects live severe cognitive disorder mental illness , outcomes measure objectively ; Subjects live alcohol drug abuse ; Subjects involve clinical study 3 month prior study ; Investigator 's opinion subject concurrent condition ( ) may put subject significant risk , may confound study result , may interfere significantly conduct study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Chronic Migraine</keyword>
	<keyword>Botulinum Toxin Type A Injection</keyword>
</DOC>